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Abstract

Key Points

IMPORTANCE Bacterial and viral causes of acute respiratory illness (ARI) are difficult to clinically
distinguish, resulting in the inappropriate use of antibacterial therapy. The use of a host gene
expression–based test that is able to discriminate bacterial from viral infection in less than 1 hour may
improve care and antimicrobial stewardship.

Question What is the ability of a host
gene expression test to accurately
discriminate bacterial from viral
infection among patients with acute
respiratory illness?

OBJECTIVE To validate the host response bacterial/viral (HR-B/V) test and assess its ability to

Findings In this diagnostic study

accurately differentiate bacterial from viral infection among patients with ARI.

involving analysis of 616 children and
adults with febrile acute respiratory

DESIGN, SETTING, AND PARTICIPANTS This prospective multicenter diagnostic study enrolled 755

illness of 7 or fewer days’ duration, the

children and adults with febrile ARI of 7 or fewer days’ duration from 10 US emergency departments.

host response bacterial/viral test had up

Participants were enrolled from October 3, 2014, to September 1, 2019, followed by additional

to 90% sensitivity, 82% specificity, and

enrollment of patients with COVID-19 from March 20 to December 3, 2020. Clinical adjudication of

98% negative predictive value for

enrolled participants identified 616 individuals as having bacterial or viral infection. The primary

bacterial infection, which was

analysis cohort included 334 participants with high-confidence reference adjudications (based on

significantly better than procalcitonin

adjudicator concordance and the presence of an identified pathogen confirmed by microbiological

measurement.

testing). A secondary analysis of the entire cohort of 616 participants included cases with

Meaning The study’s findings suggest

low-confidence reference adjudications (based on adjudicator discordance or the absence of an
identified pathogen in microbiological testing). Thirty-three participants with COVID-19 were
included post hoc.

that an accurate point-of-need host
response test with high negative
predictive value may identify patients
unlikely to have bacterial infection,

INTERVENTIONS The HR-B/V test quantified the expression of 45 host messenger RNAs in
approximately 45 minutes to derive a probability of bacterial infection.

offering a better antibiotic stewardship
strategy than is currently available.

MAIN OUTCOMES AND MEASURES Performance characteristics for the HR-B/V test compared
with clinical adjudication were reported as either bacterial or viral infection or categorized into 4
likelihood groups (viral very likely [probability score <0.19], viral likely [probability score of 0.190.40], bacterial likely [probability score of 0.41-0.73], and bacterial very likely [probability score

+ Supplemental content
Author affiliations and article information are
listed at the end of this article.

>0.73]) and compared with procalcitonin measurement.
RESULTS Among 755 enrolled participants, the median age was 26 years (IQR, 16-52 years); 360
participants (47.7%) were female, and 395 (52.3%) were male. A total of 13 participants (1.7%) were
American Indian, 13 (1.7%) were Asian, 368 (48.7%) were Black, 131 (17.4%) were Hispanic, 3 (0.4%)
were Native Hawaiian or Pacific Islander, 297 (39.3%) were White, and 60 (7.9%) were of unspecified
race and/or ethnicity. In the primary analysis involving 334 participants, the HR-B/V test had
sensitivity of 89.8% (95% CI, 77.8%-96.2%), specificity of 82.1% (95% CI, 77.4%-86.6%), and a
(continued)
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Abstract (continued)

negative predictive value (NPV) of 97.9% (95% CI, 95.3%-99.1%) for bacterial infection. In
comparison, the sensitivity of procalcitonin measurement was 28.6% (95% CI, 16.2%-40.9%;
P < .001), the specificity was 87.0% (95% CI, 82.7%-90.7%; P = .006), and the NPV was 87.6% (95%
CI, 85.5%-89.5%; P < .001). When stratified into likelihood groups, the HR-B/V test had an NPV of
98.9% (95% CI, 96.1%-100%) for bacterial infection in the viral very likely group and a positive
predictive value of 63.4% (95% CI, 47.2%-77.9%) for bacterial infection in the bacterial very likely
group. The HR-B/V test correctly identified 30 of 33 participants (90.9%) with acute COVID-19 as
having a viral infection.
CONCLUSIONS AND RELEVANCE In this study, the HR-B/V test accurately discriminated bacterial
from viral infection among patients with febrile ARI and was superior to procalcitonin measurement.
The findings suggest that an accurate point-of-need host response test with high NPV may offer an
opportunity to improve antibiotic stewardship and patient outcomes.
JAMA Network Open. 2022;5(4):e227299. doi:10.1001/jamanetworkopen.2022.7299

Introduction
Acute respiratory illness (ARI) is the most common reason for urgent health care visits.1,2 Routinely
available clinical information inadequately differentiates infections with bacterial causes from those
with viral causes, contributing to high rates of inappropriate antibiotic medication use.3-7 Tests that
reliably discriminate bacterial from viral infections could decrease diagnostic uncertainty, reduce
inappropriate use of antibacterial therapy, and improve patient outcomes.
Pathogen identification tests, such as multiplexed syndromic panels, are important diagnostic
tools but are unable to detect a bacterial or viral cause in most ARI cases.8 They also do not
distinguish colonization from infection when a microbe is identified.9,10 Because the immunological
responses to bacterial and viral infection are distinct, measuring the host response overcomes these
limitations. Procalcitonin, the most widely used host biomarker, has exhibited mixed results for
bacterial vs viral discrimination11-13 and for guiding the use of antibacterial therapy.14,15 Another
approach involves measuring peripheral blood host gene expression, which can now be performed
using clinically available platforms at the point of need.16,17
A previous study18 described the discovery of a gene expression signature discriminating
bacterial from viral illness. This signature was further developed into a research-use-only host
response bacterial/viral (HR-B/V) test via the widely used BioFire system and was evaluated using
banked samples primarily from adults in a geographically limited environment.16 The present
diagnostic study aimed to validate this HR-B/V test among a multisite diverse prospectively enrolled
cohort and assess the superiority of the HR-B/V test over procalcitonin measurement. The study
examined the feasibility and potential utility of a rapid point-of-need host response test to
differentiate bacterial from viral respiratory infections.

Methods
Study Design
This study was approved by the institutional review boards of each participating hospital. All
participants or legally authorized representatives provided written informed consent. The study
followed the Standards for Reporting of Diagnostic Accuracy (STARD) reporting guideline for
diagnostic studies.19
Participants were prospectively enrolled using convenience sampling from 10 US emergency
departments: Duke University Hospital (Durham, North Carolina), Durham VA Health Care System
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(Durham, North Carolina), UNC Health Care (Chapel Hill, North Carolina), Henry Ford Health System
(Detroit, Michigan), Brigham and Women’s Hospital (Boston, Massachusetts), University of California
Hospital at Davis (Sacramento); Children’s Memorial Hermann (McGovern Medical, Houston, Texas),
Hasbro Children’s Hospital (Providence, Rhode Island), University of Utah Medical Center (Salt Lake
City), Children’s Hospital of Pittsburgh (Pittsburgh, Pennsylvania) and Newton-Wellesley Hospital
(Newton, Massachusetts). Participants were enrolled from October 3, 2014, to September 1, 2019,
followed by additional enrollment of patients with COVID-19 from March 20 to December 3, 2020.
Included participants were 2 years or older with febrile ARI of 7 or fewer days’ duration. Acute
respiratory illness was defined as having 2 or more qualifying symptoms or 1 qualifying symptom and
at least 1 qualifying vital sign abnormality. A list of qualifying symptoms is available in eMethods in
Supplement 1. Age was categorized as follows: children (2-11 years), adolescents (12-21 years), adults
(22-64 years), and older adults (ⱖ65 years). Patients with a known or suspected infection at any
other anatomic site requiring antibacterial therapy were excluded. Charlson Comorbidity Index
scores were calculated as previously reported.20
Enrollment ended before the onset of the COVID-19 pandemic. We therefore supplemented this
analysis post hoc by analyzing blood RNA samples (PAXgene Blood RNA Tubes; QIAGEN) collected
from 33 participants with acute SARS-CoV-2 infection through convenience sampling at Duke
University or in a community setting from March to December 2020. All participants had positive
results for SARS-CoV-2 on a polymerase chain reaction test, negative results for immunoglobin G, 7
or fewer days of symptoms, and no known bacterial coinfection.

Reference Standard
Two adjudicators (including E.R.K., N.A., J.G., G.H., J.P., N.J., I.U., S.A., L. Mercurio, T.H.C., L. May,
R.W.H., J.E.L., S.H.G., D.J.P., D.S.H., K.A., R.J., L.G.T., M.T.M., C.W.W., and E.L.T. along with other
adjudicators who were not authors) from each enrollment site were randomly assigned to
independently assess the likelihood of bacterial infection, viral infection, or no infection. Details
regarding the adjudication process can be found in eMethods in Supplement 1. The primary analysis
included participants with a high-confidence reference adjudication, which was defined as
adjudicator concordance and the presence of an identified pathogen confirmed by microbiological
testing (Figure 1; eTable 1 in Supplement 1). The secondary analysis involved all participants with a
bacterial or viral infection, including those with a low-confidence adjudication, which was defined as
adjudicator discordance or the absence of an identified pathogen in microbiological testing (Figure 1;
eTable 1 in Supplement 1).

Figure 1. Study Flowchart
755 Patients with febrile acute respiratory illness
of ≤7 d enrolled
139 Excluded
83 No bacterial or viral infection
55 Indeterminate infection
1 Fungal infection
616 Patients with febrile bacterial or viral infection
of ≤7 d included in analysis

a

334 Patients with high-confidence
infection adjudications included
in primary analysis
285 Viral infection
49 Bacterial infection

616 Patients with high- and lowconfidence infection adjudications
included in secondary analysis
499 Viral infection
117 Bacterial infection

33 Patients included in COVID-19
cohorta
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Host Response Bacterial vs Viral Testing
The HR-B/V test detects 45 host messenger RNA targets using real-time quantitative reverse
transcription polymerase chain reaction testing in approximately 45 minutes; the test was developed
in collaboration with BioFire Diagnostics.18 RNA-preserved blood (PAXgene Blood RNA Tubes;
QIAGEN) was processed according to manufacturer instructions and stored at −80 °C. The HR-B/V
test was later performed by loading 100 μL of preserved blood (approximately 27 μL whole-blood
volume) directly into research-use-only HR-B/V pouches (BioFire Diagnostics), which measured the
relative abundance of target messenger RNAs normalized to the expression of 3 housekeeping genes
(DECR1, PPIB, and TRAP1). Testing was conducted at Duke University. Details regarding the test and
genes included in the panel have been previously published.16

Statistical Analysis
Test measurements for the primary and secondary analysis included sensitivity, specificity, positive
predictive value (PPV), negative predictive value (NPV), likelihood ratios, and area under the receiver
operating characteristic curve.21 The HR-B/V test results were reported as probabilities of bacterial
infection using a single threshold (probability score >0.41). We also grouped results into 4 likelihood
categories: viral very likely (probability score <0.19), viral likely (probability score of 0.19-0.40),
bacterial likely (probability score of 0.41-0.73), and bacterial very likely (probability score >0.73). The
thresholds for these interpretive groups were derived from a previously characterized cohort.16
A procalcitonin level of 0.25 ng/mL or higher indicated bacterial infection. We also used
previously described likelihood groups (<0.10 ng/mL indicated bacterial very unlikely, 0.10-0.24
ng/mL indicated bacterial unlikely, 0.25-0.50 ng/mL indicated bacterial likely, and >0.50 ng/mL
indicated bacterial very likely).22 The median value was imputed for 25 participants with
missing data.
We estimated the impact of age, sex, race and ethnicity, geographic area, hospital admission
status, comorbidities, previous antibiotic medication use, illness duration, and illness severity for test
performance using analysis of variance. Race and ethnicity were participant-defined or based on
medical records when participants could not answer. Race was included as a covariate to determine
whether it impacted the test, which measures immunological responses to infection. Bias-corrected
and accelerated bootstrapping was used to estimate 95% CIs, and permutation tests were used to
assess the statistical significance of the differences between performance measurements.23 All
analyses were performed using Matlab software, version 2016b (Mathworks). Values for the area
under the receiver operating characteristic curve were compared using the DeLong method.24 The
significance threshold was 2-tailed P = .05.

Results
Participant Characteristics
Among 755 participants enrolled in the study, the median age was 26 years (IQR, 16-52 years); 360
participants (47.7%) were female, and 395 (52.3%) were male. Participants were racially and
ethnically diverse, with 13 individuals (1.7%) identifying as American Indian, 13 (1.7%) as Asian, 368
(48.7%) as Black, 131 (17.4%) as Hispanic, 3 (0.4%) as Native Hawaiian or Pacific Islander, 297 (39.3%)
as White, and 60 (7.9%) as unspecified (Table 1). Participants without an adjudicated bacterial or
viral infection were excluded (Figure 1), resulting in 616 participants (median age, 24 years [IQR,
14-49 years]; 292 [47.4%] female and 324 [52.6%] male) included in the analyses. The median
procalcitonin level among those participants was 0.05 ng/mL (IQR, 0-0.13 ng/mL) in patients with
viral infection and 0.12 ng/mL (IQR, 0-0.47 ng/mL) in patients with bacterial infection (P = .004).
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Host Response Bacterial/Viral Test Performance
Primary Analysis
The primary analysis included 334 participants (285 with viral infection and 49 with bacterial
infection) with a high-confidence adjudication (eTable 1 in Supplement 1). Participants were first
analyzed using a single threshold (probability score ⱖ0.41, indicating bacterial infection) (Figure 2A).
In the primary analysis cohort, the HR-B/V test had sensitivity of 89.8% (95% CI, 77.8%-96.2%),
specificity of 82.1% (95% CI, 77.4%-86.6%), and an NPV of 97.9% (95% CI, 95.3%-99.1%) for
bacterial infection (Table 2; Figure 2B). Using a procalcitonin threshold of 0.25 ng/mL for bacterial
infection, sensitivity was lower at 28.6% (95% CI, 16.2%-40.9%; P < .001) but specificity was higher
at 87.0% (95% CI, 82.7%-90.7%; P = .006) compared with the HR-B/V test (Table 2; Figure 2C); the
NPV was 87.6% (95% CI, 85.5%-89.5%; P < .001). The procalcitonin area under the curve was 0.59
(95% CI, 0.49-0.68) compared with 0.92 (95% CI, 0.87-0.94) for the HR-B/V test (P < .001) (eFigure
in Supplement 1).
Dichotomizing results as either bacterial or viral with a single cutoff value (probability score
ⱖ0.41) would not have accounted for the diagnostic confidence afforded by results in the highest or
lowest groups. We therefore analyzed results using the 4-tier likelihood method. A total of 26
bacterial infections (53.1%) were classified as bacterial very likely (probability of >0.73), and 172 viral
infections (60.4%) were classified as viral very likely (probability of <0.19) (Table 3; Figure 2B). In
the viral very likely group, the NPV for bacterial infection was 98.9% (95% CI, 96.1%-100%). In the
bacterial very likely group, the PPV for bacterial infection was 63.4% (95% CI, 47.2%-77.9%) owing to
the high prevalence of viral infection (85.3%).
Procalcitonin algorithms were also applied to stratify results into 4 likelihood categories
(Figure 2A). The cohort was heavily skewed to the groups with low levels of procalcitonin: only 14

Table 1. Participant Demographic and Clinical Characteristics
Participants, No. (%)
Primary analysis

Secondary analysis

Characteristic

Enrolled

Included in analyses

Bacterial infection

Viral infection

Bacterial infection

Viral infection

Total, No.

755

616

49

285

117

499

26 (16-52)

24 (14-49)

24 (16-36)

23 (10-48)

29 (19-53)

24 (12-48)

Female

360 (47.7)

292 (47.4)

24 (49.0)

139 (48.8)

55 (47.0)

237 (47.5)

Male

395 (52.3)

324 (52.6)

25 (51.0)

146 (51.2)

62 (53.0)

262 (52.5)

American Indian

13 (1.7)

11 (1.8)

0

5 (1.8)

2 (1.7)

9 (1.8)

Asian

13 (1.7)

11 (1.8)

0

5 (1.8)

1 (0.9)

10 (2.0)

Black

368 (48.7)

293 (47.6)

23 (46.9)

135 (47.4)

46 (39.3)

247 (49.5)

Hispanic

131 (17.4)

110 (17.9)

8 (16.3)

58 (20.4)

19 (16.2)

91 (18.2)

Native Hawaiian or
Pacific Islander

3 (0.4)

2 (0.3)

0

2 (0.7)

0

2 (0.4)

Demographic
Age, median (IQR), y
Sex

Race and ethnicity

White

297 (39.3)

245 (39.8)

20 (40.8)

115 (40.4)

56 (47.9)

189 (37.9)

Unspecified

60 (7.9)

53 (8.6)

6 (12.2)

28 (9.8)

12 (10.3)

41 (8.2)

Symptom duration,
median (IQR), d

3 (2-4)

3 (2-4)

3 (2-4)

3 (2-4)

3 (2-4)

3 (2-4)

Procalcitonin level,
median (IQR), ng/mL

0.13 (0.08-0.32)

0.07 (0-0.16)

0.12 (0-0.47)

0.06 (0-0.15)

0.12 (0-0.47)

0.05 (0-0.13)

Charlson Comorbidity Index score,
mean (SD)

1.37 (2.11)

1.19 (1.94)

1.35 (2.65)

1.04 (1.60)

1.74 (2.72)

1.06 (1.68)

ICU admission

35 (4.6)

23 (3.7)

2 (4.1)

12 (4.2)

5 (4.3)

18 (3.6)

Deaths

7 (0.9)

4 (0.6)

1 (2.0)

0

4 (3.4)

0

Receipt of antibacterial therapy
before enrollment

103 (13.6)

87 (14.1)

17 (34.7)

26 (9.1)

43 (36.8)

44 (8.8)

Clinical

Abbreviation: ICU, intensive care unit.
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participants (28.6%) with bacterial infection were categorized in either of the 2 bacterial diagnostic
groups (4 individuals in the bacteria likely group and 10 individuals in the bacteria very likely group)
(Table 3; Figure 2C). For participants with procalcitonin levels lower than 0.10 ng/mL (bacterial very
unlikely group), the NPV for bacterial infection was 89.5% (95% CI, 84.6%-93.1%). For participants
with procalcitonin levels higher than 0.50 ng/mL (bacterial very likely group), we observed a PPV of
29.4% (95% CI, 15.9%-45.6%) for bacterial infection. These values were lower than those observed
for the HR-B/V test (P < .001 for both comparisons).

Figure 2. Test Performance
A Testing schemes

B

Bacterial infection

HR-B/V

Procalcitonin

0.41

Viral very
likely

Viral likely

Bacterial very
unlikely

Bacterial
unlikely

0.10 ng/mL

0.73

1.00

Bacterial
likely

Bacterial
very likely

Bacterial
likely

Bacterial
very likely

0.25 ng/mL

0.50 ng/mL

Viral infection

E

0.73

0.60
0.40

BL
0.41
VL

0.20

0.19

VVL

0

Bacterial infection

D HR-B/V results in secondary analysis

Bacterial

Procalcitonin levels in secondary analysis

F

BL
0.41
VL

0.20

0.19

VVL

0
Bacterial

10.00

1.00
0.50
0.25

BVL
BL
BU

0.10
0

Viral

BVU

HR-B/V bacterial probability

0.73

0.60
0.40

10.00

1.00
0.50
0.25

BVL
BL
BU

0.10
0

BVU

Viral

Bacterial

Viral

HR-B/V results in COVID-19 cohort
1.00

BVL

Procalcitonin, ng/mL

HR-B/V bacterial probability

1.00
0.80

Procalcitonin levels in primary analysis

BVL
0.80

Procalcitonin, ng/mL

0.19

C

HR-B/V results in primary analysis
1.00

HR-B/V bacterial probability

Viral infection

0.80

0.73

0.60

BVL
BL

0.41

0.40

VL
0.19

0.20

VVL
0

Bacterial

Viral

A, Four-group likelihood schemes for the host response bacterial/viral (HR-B/V) test and
procalcitonin measurement. In both cases (HR-B/V test vs procalcitonin measurement),
results can also be interpreted in a dichotomous manner using a single threshold. B, The
primary analysis cohort included 334 participants with high-confidence adjudications.
The line within the box indicates the median value, the box indicates the first to third
IQRs, the whiskers indicate the IQRs multiplied by 1.5, and the plus signs indicate outliers.
C, The primary analysis cohort included 334 participants with high-confidence
adjudications. The line within the box indicates the median value, the box indicates the
first to third IQRs, the whiskers indicate the IQRs multiplied by 1.5, and the plus signs
indicate outliers. D, The secondary analysis cohort included 616 participants with high-

0 10 20 30 40 50 60 70
System severity score

and low-confidence adjudications. The line within the box indicates the median value,
the box indicates the first to third IQRs, the whiskers indicate the IQRs multiplied by 1.5,
and the plus signs represent outliers. E, The secondary analysis cohort included 616
participants with high- and low-confidence adjudications. The line within the box
indicates the median value, the box indicates the first to third IQRs, the whiskers indicate
the IQRs multiplied by 1.5, and the plus signs indicate outliers. F, The COVID-19 cohort
included 33 participants with acute SARS-CoV-2 infection. The dots in panels B to F
indicate individual participants. BL indicates bacterial likely; BU, bacterial unlikely; BVL,
bacterial very likely; BVU, bacterial very unlikely; VL, viral likely; and VVL, viral very likely.

Table 2. Performance Characteristics of HR-B/V Test vs Procalcitonin Measurement for the Diagnosis of Bacterial Infection Using a Single Threshold
% (95% CI)
Sensitivity

Specificity

PPV

NPV

LR+ (95% CI)

LR− (95% CI)

AUROC (95% CI)

HR-B/V test

89.8 (77.8-96.2)

82.1 (77.4-86.6)

46.3 (39.8-53.0)

97.9 (95.3-99.1)

5.02 (3.85-6.55)

0.12 (0.05-0.29)

0.92 (0.87-0.94)

Procalcitonin
measurement

28.6 (16.2-40.9)

87.0 (82.7-90.7)

27.5 (18.1-39.3)

87.6 (85.5-89.5)

2.20 (1.29-3.76)

0.82 (0.68-0.99)

0.59 (0.49-0.68)

HR-B/V test

86.4 (79.6-92.5)

71.9 (67.7-75.9)

41.9 (38.1-45.8)

95.7 (93.4-97.3)

3.08 (2.63-3.60)

0.19 (0.12-0.30)

0.85 (0.81-0.89)

Procalcitonin
measurement

31.6 (23.3-39.5)

87.3 (84.5-90.1)

37.0 (29.2-45.5)

84.5 (82.8-86.1)

2.50 (1.76-3.56)

0.78 (0.69-0.89)

0.62 (0.56-0.67)

Analysis
Primary analysis

Secondary analysis

Abbreviations: AUROC, area under the receiver operating characteristic curve; HR-B/V, host response bacterial/viral; LR−, likelihood ratio negative; LR+, likelihood ratio positive; NPV,
negative predictive value; PPV, positive predictive value.
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Secondary Analysis
We next measured test performance among all 616 participants (499 with viral infection and 117 with
bacterial infection), including those with a low-confidence adjudication (those without confirmatory
microbiological test results or with discordant adjudications) for whom the reference standard was
expected to be less accurate. In the full cohort, the HR-B/V test had sensitivity of 86.4% (95% CI,
79.6%-92.5%) and specificity of 71.9% (95% CI, 67.7%-75.9%) when applying a single threshold to
discriminate bacterial from viral infection (Figure 2D; Table 2). As observed in the primary analysis,
procalcitonin measurement was less sensitive (31.6%; 95% CI, 23.3%-39.5%; P < .001) but more
specific (87.3%; 95% CI, 84.5%-90.1%; P = .005) than the HR-B/V test (Figure 2E), with an NPV of
84.5% (95% CI, 82.8%-86.1%) for bacterial infection. The procalcitonin area under the receiver
operating characteristic curve was 0.62 (95% CI, 0.56-0.67) compared with 0.85 (95% CI,
0.81-0.89) for the HR-B/V test (P < .001) (eFigure in Supplement 1). When considering all 4 HR-B/V
likelihood groups, the viral very likely group had an NPV of 96.7% (95% CI, 94.2%-98.4%), whereas

Table 3. Performance Characteristics of HR-B/V Test vs Procalcitonin Measurement for the Diagnosis of Bacterial Infection Using a 4-Group Likelihood Scheme
No./total No. (%)

% (95% CI)

Bacterial infection

Viral infection

PPV in groupa

NPV in groupa

Sensitivityb

Specificityb

Interval likelihood
ratio (95% CI)c

VVL (probability
score <0.19)

2/49 (4.1)

172/285 (60.4)

NA

98.9 (96.1-100)

NA

60.4 (54.7-66.0)

0.07 (0-0.20)

VL (probability
score 0.19-0.40)

3/49 (6.1)

62/285 (21.8)

NA

95.4 (88.1-98.7)

NA

21.8 (17.0-26.9)

0.28 (0-0.77)

BL (probability
score 0.41-0.73)

18/49 (36.7)

36/285 (12.6)

33.3 (22.9-48.3)

NA

36.7 (23.4-50.8)

NA

2.91 (1.76-4.74)

BVL (probability
score >0.73)

26/49 (53.1)

15/285 (5.3)

63.4 (47.2-77.9)

NA

53.1 (38.8-67.4)

NA

10.08 (5.69-17.36)

BVU (<0.10 ng/mL) 22/49 (44.9)

187/285 (65.6)

NA

89.5 (84.6-93.1)

NA

65.6 (59.9-70.6)

0.68 (0.49-0.94)

BU (0.10-0.24
ng/mL)

13/49 (26.5)

61/285 (21.4)

NA

82.4 (72.0-90.4)

NA

21.4 (17.1-26.8)

1.24 (0.72-2.12)

BL (0.25-0.50
ng/mL)

4/49 (8.2)

13/285 (4.6)

23.5 (6.7-50.0)

NA

8.2 (2.3-18.3)

NA

1.79 (0.41-5.82)

BVL (>0.50 ng/mL)

10/49 (20.4)

24/285 (8.4)

29.4 (15.9-45.6)

NA

20.4 (10.3-33.9)

NA

2.42 (1.17-4.90)

VVL (probability
score <0.19)

8/117 (6.8)

238/499 (47.7)

NA

96.7 (94.2-98.4)

NA

47.7 (43.6-52.3)

0.14 (0.07-0.27)

VL (probability
score 0.19-0.40)

8/117 (6.8)

121/499 (24.2)

NA

93.8 (87.9-96.9)

NA

24.2 (20.7-28.5)

0.28 (0.12-0.56)

BL (probability
score 0.41-0.73)

36/117 (30.8)

95/499 (19.0)

27.5 (20.0-35.7)

NA

30.8 (22.6-39.7)

NA

1.62 (1.19-2.27)

BVL (probability
score >0.73)

65/117 (55.6)

45/499 (9.0)

59.1 (49.7-67.9)

NA

55.6 (46.5-63.9)

NA

6.16 (4.55-8.59)

BVU (<0.10 ng/mL) 53/117 (45.3)

332/499 (66.5)

NA

86.2 (82.7-89.5)

NA

66.5 (61.9-70.8)

0.68 (0.54-0.82)

BU (0.10-0.24
ng/mL)

27/117 (23.1)

104/499 (20.8)

NA

79.4 (71.7-85.6)

NA

20.8 (17.7-24.7)

1.11 (0.74-1.59)

BL (0.25-0.50
ng/mL)

11/117 (9.4)

30/499 (6.0)

26.8 (15.0-42.8)

NA

9.4 (5.1-15.9)

NA

1.56 (0.75-3.02)

BVL (>0.50 ng/mL)

26/117 (22.2)

33/499 (6.6)

44.1 (30.4-57.1)

NA

22.2 (15.4-30.5)

NA

3.36 (2.06-5.24)

Test and group
Primary analysis
HR-B/V test

Procalcitonin
measurement

Secondary analysis
HR-B/V test

Procalcitonin
measurement

Abbreviations: BL, bacterial likely; BU, bacterial unlikely; BVL, bacterial very likely; BVU,
bacterial very unlikely; HR-B/V, host response bacterial/viral; NA, not applicable; NPV,
negative predictive value; PPV, positive predictive value; VL, viral likely; VVL, viral
very likely.
a

PPV and NPV were used for the diagnosis of bacterial infection.

b

Sensitivity and specificity were calculated as the percentage of adjudicated
participants in each band. The test’s overall sensitivity and specificity were calculated

as the sum of values in the respective cells. For example, the HR-B/V test had a
sensitivity of 89.8% (53.1% plus 36.7%) for results in the BVL or BL groups and a
specificity of 82.2% (60.4% plus 21.8%) for results in the VVL or VL groups.
c

Likelihood ratios were used for the diagnosis of bacterial infection. Values in the BVL
and BL groups correspond to positive likelihood ratios, whereas values in the VL and
VVL correspond to negative likelihood ratios.
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the bacterial very likely group had a PPV of 59.1% (95% CI, 49.7%-67.9%) for bacterial infection.
Additional test characteristics are shown in Table 3. A procalcitonin level of lower than 0.10 ng/mL
had an NPV of 86.2% (95% CI, 82.7%-89.5%) for bacterial infection (P < .001 vs the HR-B/V test). A
procalcitonin level higher than 0.50 ng/mL had a PPV of 44.1% (95% CI, 30.4%-57.1%) for bacterial
infection (P = .005 vs the HR-B/V test).

Test Performance in Clinical Subgroups
We did not observe any significant differences in HR-B/V test performance based on age, enrollment
site, race, ethnicity, or sex in either the primary or secondary analysis (eTable 2 in Supplement 1).
Performance was unchanged by the presence of comorbidities, including coronary artery disease,
heart failure, chronic kidney disease, chronic lung disease, diabetes, or the composite Charlson
Comorbidity Index score. Using hospitalization as a surrogate for illness severity, we observed a
higher overall accuracy among hospitalized vs nonhospitalized participants (78.2% vs 73.2%;
P = .002). Treatment vs nontreatment with antibacterial therapy 8 hours or more before sample
collection did not impact test performance as measured by overall accuracy (75.9% vs 74.5%;
P = .73). Duration of illness, assessed in daily increments, also did not impact test performance (eg,
0-1 days vs 7 days since symptom onset: 76.6% vs 77.3%; P = .55). The test was less accurate among
participants with enterovirus or rhinovirus (59.3%; 95% CI, 49.9%-68.3%) compared with
participants with all other viral infections (90.2%; 95% CI, 85.9%-93.6%; P < .001) (eTable 3 in
Supplement 1).

Antibacterial Therapy Use
This study did not directly measure the impact of HR-B/V testing on antibacterial therapy use
because testing was not performed in real time. We estimated the potential association if results had
been available. In the primary analysis involving 334 participants, 234 individuals were adjudicated
as having viral infections, 84 of whom (35.9%) were prescribed antibacterial therapy. These 84
participants represented opportunities for reduced antibacterial medication use. In contrast, the
HR-B/V test misclassified 51 participants as having bacterial infections, 30 of whom (58.8%) were not
prescribed antibacterial therapy. Therefore, adherence to HR-B/V test results would have had the
net result of eliminating inappropriate antibacterial therapy use in 54 of 334 cases (16.2%).

Classification of COVID-19 Cases
Among 33 participants with acute COVID-19, the HR-B/V test correctly classified 30 participants
(90.9%) as having a viral infection (24 in the viral very likely group and 6 in the viral likely group).
There was no apparent association between HR-B/V test results and participant-reported symptom
severity (Figure 2F). In particular, the symptom severities were similar among the 3 misclassified
participants compared with those who were correctly classified as having a viral infection.

Discussion
This diagnostic study found an NPV of up to 97.9% for bacterial infection using a rapid host gene
expression test to discriminate bacterial from viral infection among a large multicenter
heterogeneous pediatric and adult population. Antimicrobial resistance is currently increasing at a
concerning rate, owing in part to inappropriate use of antibacterial therapy.6 Moreover, antibacterial
medications pose risks to the individual patient, including allergic reactions, drug-drug interactions,
and Clostridium difficile infections.25,26 To address this diagnostic challenge, we developed a test that
discriminated bacterial from viral infection by measuring the host’s gene expression response. This
study validated the performance of a research-use-only HR-B/V test for the discrimination of
bacterial vs viral infection among 616 participants with febrile ARI. The gene expression test was
superior to measurement of procalcitonin, a widely used host response peptide biomarker that has
been validated among patients with lower respiratory tract infections. The test also worked equally
JAMA Network Open. 2022;5(4):e227299. doi:10.1001/jamanetworkopen.2022.7299 (Reprinted)
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well among participants with acute COVID-19. Although we did not assess the combined
performance of the HR-B/V test and procalcitonin measurement, a previous study27 found no
improvement vs HR-B/V testing alone.
The potential utility of a test distinguishing bacterial from viral infection is highly dependent on
the prevalence of these conditions.18 When the prevalence of viral infection is high, as in most cases
of ARI, a moderately accurate test would have a high NPV for bacterial infection. As a consequence,
such a test does not need to have perfect accuracy to be clinically valuable. For example, despite
55% sensitivity and 76% specificity for procalcitonin measurement to detect bacterial pneumonia,
the biomarker’s use has been reported to decrease unnecessary prescription of antibacterial
therapy.13,15 However, this antibacterial-sparing outcome was not observed in the Procalcitonin
Antibiotic Consensus Trial,14 a randomized clinical trial of procalcitonin measurement compared with
standard of care among patients in the emergency department with lower respiratory tract
infections. The reasons for this finding are likely multifactorial, although an insufficient NPV is a likely
factor. Compared with procalcitonin measurement, the significantly higher NPV for the HR-B/V test
(97.9%) suggests it may have even greater clinical utility, which will need to be verified in a
prospective clinical utility study. The most helpful use of the test would therefore be a result
indicating the absence of bacterial infection, especially in settings in which the prevalence of such
infections is low, as it is with ARI cases. In the present study, we observed a potential reduction of at
least 16.2%, even after accounting for false bacterial infection diagnoses in which antibacterial
therapy might have been overprescribed. This reduction did not account for scenarios in which
clinicians may have chosen to nevertheless prescribe antibacterial therapy, resulting in a lower effect
size than we found possible. The test’s potential value will also depend on how easily it can be
integrated into clinical workflows.
High rates of antibacterial medication overuse have occurred during the COVID-19 pandemic
because of uncertainty about the presence of bacterial infection.6,7 Although the HR-B/V test was
developed before the pandemic, participants with COVID-19 were identified as having viral infection
without a concurrent bacterial infection, offering a tool to support antimicrobial stewardship. We
were unable to identify cases of SARS-CoV-2 and bacterial coinfection; therefore, we could not draw
any conclusions about test performance in this scenario, although this is an important clinical group
to investigate. This caveat applies to cases of bacterial and viral coinfection in general, which were
inadequately represented in the present cohort. However, a previous study16 found that the HR-B/V
test signature identified bacterial infection in 100% of microbiologically confirmed bacterial and viral
coinfection. It has also previously been reported that host gene expression can distinguish bacterial,
viral, and noninfectious illness in patients with immunocompromising conditions.28
One challenge when evaluating tests for bacterial vs viral discrimination is the absence of a
diagnostic criterion standard. Adjudication has often been used, with 1 study29 reporting reasonable
interobserver agreement (κ = 0.88). However, the reliability of this reference decreases in several
situations. For example, the absence of microbiological confirmation or discordant adjudications has
been associated with lower test accuracy for other biomarkers.30 The present study revealed similar
findings in which test accuracy decreased among participants with a low-confidence adjudication,
defined as having no supportive microbiological results or discordant adjudications (secondary
analysis cohort). This decrease was not likely to be associated with inadequate test performance but
rather with errors in the reference standard used.
The development and validation of this research-use-only HR-B/V test measured using the
BioFire Diagnostics system has been previously described.16 The current study confirms those
findings while encompassing a broader age range, multiple sites, and a more racially and ethnically
heterogeneous cohort. We did not observe any significant differences owing to sex, age, race,
ethnicity, enrollment site, comorbidity, or hospitalization status. A previous study18 evaluating this
test included patients with noninfectious illness. Although inclusion of these patients increased the
population available for testing, it came at the expense of test accuracy. In particular, test
performance decreased as the number of clinical categories increased.18,31 Therefore, the present
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study focused on the narrower indication of acute (ⱕ7 days) febrile respiratory illness suspected to
be caused by bacterial or viral infection.
Measuring gene expression simply, rapidly, and reliably requires the convergence of multiple
technologies, including blood cell lysis, RNA purification, RNA preservation or rapid processing, and
quantitative real-time reverse transcription amplification (emerging technologies could substitute
for some of these elements). This process has been conducted using slower high-complexity
research tools, such as low-density array cards (TaqMan; Thermo Fisher Scientific) or nanostring
arrays (NanoString Technologies).28,32-34 There has been more limited progress in the development
of rapid sample-to-answer tests. Sutherland et al17 described a host gene expression test for the
diagnosis of tuberculosis using a molecular analyzer (GeneXpert System; Cepheid). Other studies
have described the successful translation of host gene expression tests for viral infection and
bacterial vs viral discrimination using 2 different platforms (Qvella Corporation and BioFire
Diagnostics, respectively).16,35 This previous work included participants with bacterial and viral
coinfection, finding the ability to detect host responses to both pathogens. The present study
extended those findings, highlighting the opportunity to develop host gene expression–based
diagnostic assessments for a variety of clinical applications. Signatures have been described for
infectious disease applications (eg, sepsis, candidemia, Dengue, tuberculosis, and malaria)36-47 and
noncommunicable diseases (eg, rheumatic diseases, coronary artery disease, radiation exposure,
and cancer).48-53 As the path from signature discovery to test development and commercialization
comes into focus, we expect the development and use of point-of-need host response–based
diagnostic tools to expand.

Limitations
This study has several limitations. These limitations include the use of clinical adjudication as an
imperfect reference standard. This study did not address elements of analytical validation, such as
site-to-site or run-to-run variability, nor did it evaluate patients with nonrespiratory infections.
Furthermore, tests that discriminate bacterial from viral infection are only useful if clinicians modify
their antibacterial medication use accordingly. Although we found a reduction in the use of
antibacterial therapy is possible, this study did not address clinical utility. We did not identify
demographic or clinical variables associated with test performance. Although hospitalization as a
marker of severity did not impact test performance, there were too few participants with critical
illness defined by intensive care unit admission to evaluate the test in this subgroup. There were also
too few participants with bacterial and viral coinfection to compare results with those of other
published reports. Serial HR-B/V test measurements would help to define a role for the test in
treatment-response monitoring.

Conclusions
This diagnostic study found that host gene expression could be measured at the point of need using
a readily available clinical platform. The gene expression biomarkers included in the HR-B/V test
accurately distinguished bacterial from viral infections among participants with acute febrile
respiratory tract infections. Test performance was superior to procalcitonin measurement and was
also accurate among participants with COVID-19.
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